Repligen (FRA:RGN) Long-Term Capital Lease Obligation : €128.5 Mil (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Repligen Long-Term Capital Lease Obligation?

Repligen's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €128.5 Mil.

Repligen's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (€125.0 Mil) to Dec. 2024 (€139.0 Mil) but then declined from Dec. 2024 (€139.0 Mil) to Mar. 2025 (€128.5 Mil).

Repligen's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (€124.0 Mil) to Dec. 2023 (€116.1 Mil) but then increased from Dec. 2023 (€116.1 Mil) to Dec. 2024 (€139.0 Mil).

Repligen Long-Term Capital Lease Obligation Historical Data

The historical data trend for Repligen's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Long-Term Capital Lease Obligation Chart

Repligen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

21.72

90.71

124.03

116.07

139.03

Repligen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															132.99	133.33	124.96	139.03	128.52

Repligen (FRA:RGN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Repligen Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Repligen's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

RGEN:USA RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Headlines

No Headlines